Sanofi (NASDAQ:SNY) is one of the best blue-chip stocks to buy for 2026. On January 5, the US Food and Drug Administration ...
The FDA has approved Zycubo (copper histidinate) injection as the first and only treatment of Menkes disease in pediatric ...
Results of the SPACE trial demonstrating the safety and efficacy of subcutaneous fremanezumab for the prevention of pediatric ...
The treatment for acquired thrombotic thrombocytopenic purpura, a rare blood disorder that causes blood clots in the small ...
Credit: Getty Images. The FDA has issued a safety alert regarding the use of unapproved potassium phosphates drug products in pediatric patients. The Food and Drug Administration (FDA) has issued a ...
Please provide your email address to receive an email when new articles are posted on . Fears associated with needles may cause patients and caregivers to delay their use of epinephrine autoinjectors.
~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-metastatic Solid Tumors ~ ~ The ...
Please provide your email address to receive an email when new articles are posted on . Results showed the addition of a single-injection proximal sciatic nerve block to an adductor canal block ...
TARRYTOWN, N.Y., Oct. 21, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (REGN) today announced the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for EYLEA ® ...
Enrollment of pivotal cohort expected to begin in Q1 2026; ATSN-201 BLA submission on track for early 2028DURHAM, N.C., Jan. 08, 2026 (GLOBE ...
Zycubo is a copper replacement therapy administered via subcutaneous injection to bypass impaired GI absorption in patients with Menkes disease.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results